Drug intelligence / Profile preview

ethoximod

Development stage: Phase 1
Lead developer: Beijing Union Pharmaceutical Factory
Modality: Small Molecules
Administration: Oral

Overview

Ethoximod is an investigational small molecule drug that acts as an agonist of the sphingosine 1-phosphate receptor 1 (S1PR1). It was initially developed by Beijing Union Pharmaceutical Factory and has been studied in early-phase clinical trials for its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The primary mechanism involves modulation of S1PR1, which is implicated in immune cell trafficking and inflammatory processes. Ethoximod has reached Phase 1 clinical development for indications such as psoriasis[3][8].

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on ethoximod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethoximod.

Explore the full profile